A case of myeloid neoplasm with the PDGFRB rearrangement and eosinophilia.
- Author:
Sang Eon JANG
1
;
Hye Jin KANG
;
Yoon Hwan CHANG
;
Dong Soon LEE
;
Hyeon Tae KIM
;
Kyung Won KOH
;
Sung Hyun YANG
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea. hyejin@kcch.re.kr
- Publication Type:Case Report
- Keywords:
Myeloid neoplasm;
PDGFRB rearrangement;
Eosinophilia;
Imatinib mesylate
- MeSH:
Aged, 80 and over;
Benzamides;
Bone Marrow;
Cough;
Eosinophilia;
Female;
Fluorescence;
Humans;
In Situ Hybridization;
Piperazines;
Pyrimidines;
Receptor, Platelet-Derived Growth Factor beta;
Receptors, Platelet-Derived Growth Factor;
Thrombocytosis;
Imatinib Mesylate
- From:Korean Journal of Medicine
2010;78(3):386-390
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Myeloid neoplasm with the platelet-derived growth factor receptor beta (PDGFRB) rearrangement is a myeloproliferative neoplasm. Patients with this disease often have prominent eosinophilia or monocytosis and the presence of t(5;12)(q31~33;p12) or a variant translocation with expression of an ETV6-PDGFRB fusion gene or the PDGFRB rearrangement. We report an 82-year-old woman with a myeloid neoplasm, with the PDGFRB rearrangement, who presented with a dry cough, eosinophilia and thrombocytosis. The chromosome study of the bone marrow showed 46,XX,ins(1;5)(q22;q33q13.3), and fluorescence in situ hybridization (FISH) analysis revealed rearrangement of the PDGFRB gene. The patient was successfully treated with low-dose imatinib.
